Full Press Release Details
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC.
IMMP
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Key Takeaway: Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)